Curtis Robert Chong, MD
Medical Oncology · Redwood City
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Sequoia Hospital · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chong’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A143956 · Current
Licensed to practise in California · since 2016 · expires 2027-09-30 · Johns Hopkins University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Sequoia HospitalRedwood City, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 104.12 (51.8 to 156.44) · 56 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Sequoia Hospital
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 104.12 (51.8 to 156.44) · 56 cases | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0 to 1.98) · 472 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.91 (0.58 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.8 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.1 · 258 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.5 · 171 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 81 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,231 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.23 (0.01 to 0.44) · 3,018 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.44) · 3,164 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.59 (0.47 to 4.71) · 1,402 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.47 (0.04 to 2.9) · 926 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.68 (0.21 to 3.16) · 1,310 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.54 (4.42 to 14.67) · 978 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.98 (1.61 to 8.36) · 924 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.69 (0.19 to 3.19) · 192 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.57 (0 to 1.43) · 2,501 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.5 · 332 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.702 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.853 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 67 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 295 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -27.1 · 76 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -22.3 · 304 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4.6 · 178 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.3 · 180 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 305 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 41 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 29 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (9.7 to 17.7) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 713 cases | No different | Jan 2024 – Dec 2024 |
What patients said (631 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 82% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 81% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 91% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$370,075
Medicare paid this office $370,075 for 371 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 295 | $184,562 | $157 |
| Return visit (30+ min) | 275 | $104,210 | $114 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 317 | $29,810 | $15 |
| Short return visit (20+ min) | 130 | $22,980 | $80 |
| New patient visit (60+ min) | 103 | $20,396 | $198 |
See all 6 services
| Long return visit (40+ min) | 295 | $184,562 | $157 |
| Return visit (30+ min) | 275 | $104,210 | $114 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 317 | $29,810 | $15 |
| Short return visit (20+ min) | 130 | $22,980 | $80 |
| New patient visit (60+ min) | 103 | $20,396 | $198 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 88 | $3,757 | $29 |
Who their Medicare patients are
371 Original Medicare patients in 2024. Average age 75 · Under 65 9% · 85 and older 15% · Women 49% · Also on Medicaid 35% · Health risk score 2.41. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: High blood pressure 75% · Cancer 51% · Diabetes 42% · Coronary heart disease 39% · Chronic kidney disease 31% · Heart failure 21% · Atrial fibrillation 21% · COPD 17% · Depression 16% · Dementia 10% · Stroke 9%.
The office billed $2,087,348, Medicare allowed $479,411 and paid $370,075; for 4,691 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 371 | 4,691 | 75 | 2.41 | $2,087,348 | $370,075 |
| 2023 | 352 | 2,966 | 76 | 2.73 | $1,883,801 | $286,028 |
| 2022 | 418 | 3,039 | 75 | 2.72 | $1,785,422 | $275,493 |
| 2021 | 238 | 2,630 | 75 | 2.30 | $1,454,284 | $240,879 |
| 2020 | 206 | 2,023 | 76 | 2.08 | $824,650 | $169,492 |
| 2019 | 171 | 742 | 75 | 2.63 | $191,209 | $65,602 |
| 2018 | 153 | 778 | 73 | 3.17 | $427,245 | $59,317 |
| 2017 | 111 | 559 | 74 | 2.00 | $298,235 | $42,786 |
| 2016 | 115 | 189 | 75 | 3.35 | $86,195 | $18,781 |
| 2015 | 108 | 123 | 73 | 3.03 | $70,114 | $16,140 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Long return visit (40+ min) | 255 | $150,132 | $126 |
| Return visit (30+ min) | 225 | $74,351 | $84 |
| Short return visit (20+ min) | 156 | $22,580 | $55 |
| New patient visit (60+ min) | 75 | $11,599 | $155 |
| Long return visit (40+ min) | 24 | $5,328 | $130 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $5,065 | $108 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 113 | $4,844 | $27 |
| New patient visit (60+ min) | 21 | $3,427 | $163 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,344 | $156 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $2,014 | $72 |
| Return visit (30+ min) | 11 | $1,765 | $84 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 23 | $765 | $28 |
2022: 16 services
| Long return visit (40+ min) | 208 | $90,709 | $128 |
| Return visit (30+ min) | 222 | $72,565 | $84 |
| Short return visit (20+ min) | 192 | $37,382 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 121 | $22,577 | $92 |
| New patient visit (60+ min) | 91 | $15,453 | $170 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 47 | $8,549 | $178 |
| New patient visit (60+ min) | 25 | $4,159 | $166 |
| Long return visit (40+ min) | 22 | $4,137 | $133 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 73 | $3,912 | $28 |
| Return visit (30+ min) | 21 | $3,776 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $2,696 | $64 |
| Extended inpatient or observation hospital service, first hour | 19 | $1,737 | $83 |
| Short return visit (20+ min) | 14 | $1,639 | $61 |
| Hospital discharge day management, more than 30 minutes | 15 | $1,459 | $97 |
| Short return visit | 21 | $831 | $31 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 15 | $620 | $28 |
2021: 10 services
| Long return visit (40+ min) | 187 | $104,709 | $130 |
| Return visit (30+ min) | 185 | $73,630 | $86 |
| Short return visit (20+ min) | 153 | $32,077 | $58 |
| New patient visit (60+ min) | 54 | $8,875 | $164 |
| Long return visit (40+ min) | 28 | $5,888 | $137 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 63 | $4,248 | $29 |
| Return visit (30+ min) | 26 | $3,764 | $86 |
| New patient visit (60+ min) | 22 | $3,743 | $170 |
| Short return visit | 30 | $1,893 | $33 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 16 | $1,019 | $30 |
2020: 7 services
| Long return visit (40+ min) | 171 | $79,968 | $99 |
| Return visit (30+ min) | 162 | $66,123 | $70 |
| New patient visit (60+ min) | 52 | $7,837 | $151 |
| Short return visit (20+ min) | 63 | $5,542 | $47 |
| New patient visit (60+ min) | 23 | $3,573 | $155 |
| Return visit (30+ min) | 21 | $2,261 | $73 |
| Long return visit (40+ min) | 15 | $2,166 | $103 |
2019: 5 services
| Long return visit (40+ min) | 103 | $39,858 | $97 |
| Return visit (30+ min) | 76 | $12,351 | $67 |
| New patient visit (60+ min) | 42 | $5,847 | $139 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $3,407 | $87 |
| Short return visit (20+ min) | 27 | $1,724 | $41 |
2018: 4 services
| Long return visit (40+ min) | 83 | $29,300 | $92 |
| Return visit (30+ min) | 93 | $19,284 | $65 |
| Short return visit (20+ min) | 40 | $3,997 | $41 |
| New patient visit (60+ min) | 26 | $3,690 | $142 |
2017: 5 services
| Return visit (30+ min) | 66 | $15,182 | $66 |
| Long return visit (40+ min) | 64 | $14,752 | $93 |
| New patient visit (60+ min) | 55 | $7,802 | $142 |
| Short return visit (20+ min) | 36 | $3,464 | $43 |
| Short return visit | 16 | $535 | $21 |
2016: 4 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 53 | $8,092 | $153 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $3,453 | $82 |
| Critical care, first 30-74 minutes | 14 | $2,538 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $2,510 | $58 |
2015: 3 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 71 | $12,040 | $167 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $1,547 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $776 | $60 |
Medicaid work
$112,445 in 2024
Medicaid paid $112,445 for 2,032 billed services this clinician did in 2024, up to 70 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 885 | $80,019 |
| Return visit (30+ min) | 510 | $28,183 |
| Short return visit (20+ min) | 76 | $2,652 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 561 | $1,592 |
| 2024 | 2,032 | 4 | 70 | $112,445 |
| 2023 | 1,931 | 4 | 68 | $85,929 |
| 2022 | 1,963 | 6 | 49 | $87,809 |
| 2021 | 1,201 | 3 | 33 | $49,126 |
| 2020 | 349 | 2 | 18 | $13,920 |
| 2019 | 103 | 1 | 14 | $6,163 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 956 | $51,394 |
| Return visit (30+ min) | 672 | $25,829 |
| Short return visit (20+ min) | 272 | $7,273 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 31 | $1,434 |
2022
| Long return visit (40+ min) | 558 | $34,574 |
| Return visit (30+ min) | 681 | $32,226 |
| Short return visit (20+ min) | 502 | $14,327 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 122 | $5,658 |
| Telehealth originating site facility fee | 81 | $1,024 |
| Advance Care Planning discussed and documented advance care plan or surrogate decision maker documented in the medical record (DEM) (GER, Pall Cr) | 19 | $0 |
2021
| Long return visit (40+ min) | 422 | $23,406 |
| Return visit (30+ min) | 489 | $18,914 |
| Short return visit (20+ min) | 290 | $6,805 |
2020
| Long return visit (40+ min) | 216 | $9,802 |
| Return visit (30+ min) | 133 | $4,118 |
2019
| Long return visit (40+ min) | 103 | $6,163 |
Drugs they prescribed that Part D paid
$1,375,390
Pharmacies billed $1,375,390 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 6% of their Part D prescriptions (116 of 2,038) in 2024. Above the middle of the specialty; the typical medical oncology clinician is at 6%. Long-acting opioids: 28% of their opioid prescriptions.
1,679 generic and fewer than 11 brand-name prescriptions · $1,375,390 in drug cost · 74 antibiotic prescriptions to 29 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Stivarga | 23 | $343,566 | $14,938 |
| Creon | 54 | $102,616 | $1,900 |
| Eliquis | 80 | $77,066 | $963 |
| Zarxio | 26 | $34,790 | $1,338 |
| Xarelto | 24 | $22,994 | $958 |
See all 48 drugs
| Stivarga | 23 | $343,566 | $14,938 |
| Creon | 54 | $102,616 | $1,900 |
| Eliquis | 80 | $77,066 | $963 |
| Zarxio | 26 | $34,790 | $1,338 |
| Xarelto | 24 | $22,994 | $958 |
| Enoxaparin | 51 | $11,332 | $222 |
| Jardiance | 13 | $10,218 | $786 |
| Mirtazapine | 50 | $1,976 | $40 |
| Sucralfate | 14 | $1,652 | $118 |
| Ondansetron | 118 | $1,494 | $13 |
| Prochlorperazine Maleate | 136 | $1,381 | $10 |
| Sodium Chloride | 35 | $1,223 | $35 |
| Naloxone | 21 | $1,067 | $51 |
| Nystatin | 18 | $1,017 | $56 |
| Gabapentin | 71 | $928 | $13 |
| Dexamethasone | 53 | $922 | $17 |
| Potassium Chloride | 44 | $807 | $18 |
| Morphine Sulfate Er | 28 | $719 | $26 |
| Oxycodone | 51 | $630 | $12 |
| Hydrocortisone | 18 | $623 | $35 |
| Lactulose | 27 | $620 | $23 |
| Celecoxib | 20 | $541 | $27 |
| Ondansetron Odt | 13 | $538 | $41 |
| Amlodipine Besylate | 66 | $483 | $7 |
| Doxycycline Hyclate | 21 | $479 | $23 |
| Lidocaine-Prilocaine | 35 | $438 | $13 |
| Alendronate | 38 | $427 | $11 |
| Chlorthalidone | 16 | $411 | $26 |
| Hydrocodone-Acetaminophen | 14 | $408 | $29 |
| Lisinopril | 37 | $408 | $11 |
| Anastrozole | 18 | $341 | $19 |
| Prednisone | 39 | $328 | $8 |
| Loperamide | 16 | $265 | $17 |
| Losartan | 16 | $261 | $16 |
| Levothyroxine | 33 | $247 | $7 |
| Atorvastatin | 36 | $236 | $7 |
| Pantoprazole | 19 | $230 | $12 |
| Metformin | 14 | $193 | $14 |
| Metoprolol | 15 | $189 | $13 |
| Tamsulosin | 22 | $166 | $8 |
| Spironolactone | 23 | $165 | $7 |
| Amoxicillin-Clavulanate Potass | 18 | $155 | $9 |
| Furosemide | 34 | $136 | $4 |
| Trazodone | 15 | $125 | $8 |
| Lorazepam | 42 | $114 | $3 |
| Tramadol | 13 | $78 | $6 |
| Metformin Hcl Er | 15 | $61 | $4 |
| Escitalopram | 12 | $38 | $3 |
Year by year
| 2024 | 2,038 | 241 | 6% (116) | None | $1,375,390 |
| 2023 | 1,919 | 213 | 7% (138) | None | $1,597,929 |
| 2022 | 1,743 | 180 | 11% (184) | None | $2,588,981 |
| 2021 | 1,363 | 150 | 11% (143) | None | $2,146,418 |
| 2020 | 1,000 | 127 | 9% (87) | 23% | $1,438,738 |
| 2019 | 333 | 72 | 9% (31) | 25% | $665,912 |
| 2018 | 361 | 88 | 13% (48) | None | $297,712 |
| 2017 | 462 | 105 | 11% (52) | None | $435,612 |
| 2016 | 39 | 24 | None | None | $46,501 |
| 2015 | 62 | 16 | None | 24% | $19,019 |
| 2014 | 20 | None | None | None | $9,208 |
| 2013 | 69 | 13 | None | 25% | $48,553 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 47 drugs
| Lenvima | 21 | $500,595 | $23,838 |
| Stivarga | 22 | $357,015 | $16,228 |
| Eliquis | 91 | $74,039 | $814 |
| Creon | 34 | $35,914 | $1,056 |
| Xarelto | 18 | $12,793 | $711 |
| Enoxaparin | 35 | $10,651 | $304 |
| Sodium Chloride | 70 | $3,090 | $44 |
| Mirtazapine | 49 | $2,321 | $47 |
| Pantoprazole | 26 | $1,889 | $73 |
| Lactulose | 34 | $1,692 | $50 |
| Naloxone | 20 | $1,656 | $83 |
| Gabapentin | 83 | $1,645 | $20 |
| Oxycodone | 65 | $1,548 | $24 |
| Prochlorperazine Maleate | 116 | $1,353 | $12 |
| Dexamethasone | 44 | $1,182 | $27 |
| Amlodipine Besylate | 78 | $1,048 | $13 |
| Ondansetron | 100 | $968 | $10 |
| Potassium Chloride | 34 | $929 | $27 |
| Morphine Sulfate Er | 36 | $923 | $26 |
| Hydrocortisone | 19 | $812 | $43 |
| Atorvastatin | 32 | $790 | $25 |
| Celecoxib | 16 | $789 | $49 |
| Alendronate | 39 | $742 | $19 |
| Loperamide | 29 | $670 | $23 |
| Tamoxifen Citrate | 19 | $574 | $30 |
| Levothyroxine | 21 | $548 | $26 |
| Spironolactone | 21 | $542 | $26 |
| Losartan | 24 | $533 | $22 |
| Chlorthalidone | 14 | $483 | $34 |
| Ketoconazole | 11 | $440 | $40 |
| Prednisone | 43 | $413 | $10 |
| Tamsulosin | 17 | $380 | $22 |
| Lisinopril | 23 | $372 | $16 |
| Lidocaine-Prilocaine | 25 | $338 | $14 |
| Anastrozole | 18 | $322 | $18 |
| Omeprazole | 12 | $240 | $20 |
| Trazodone | 14 | $234 | $17 |
| Escitalopram | 15 | $210 | $14 |
| Metformin | 12 | $175 | $15 |
| Mupirocin | 11 | $171 | $16 |
| Metoprolol | 11 | $170 | $15 |
| Tramadol | 13 | $140 | $11 |
| Lorazepam | 27 | $130 | $5 |
| Hydrocodone-Acetaminophen | 11 | $127 | $12 |
| Furosemide | 30 | $117 | $4 |
| Triamcinolone Acetonide | 11 | $107 | $10 |
| Hydrochlorothiazide | 12 | $97 | $8 |
2022: 43 drugs
| Lenvima | 22 | $590,310 | $26,832 |
| Pomalyst | 19 | $404,627 | $21,296 |
| Imbruvica | 12 | $134,295 | $11,191 |
| Eliquis | 86 | $72,165 | $839 |
| Creon | 23 | $36,165 | $1,572 |
| Xgeva | 11 | $31,842 | $2,895 |
| Plenamine | 16 | $5,854 | $366 |
| Sucralfate | 18 | $4,085 | $227 |
| Oxycontin | 13 | $3,956 | $304 |
| Naloxone | 32 | $2,515 | $79 |
| Dexamethasone | 37 | $1,935 | $52 |
| Nystatin | 28 | $1,904 | $68 |
| Ondansetron | 88 | $1,530 | $17 |
| Mirtazapine | 36 | $1,143 | $32 |
| Pantoprazole | 14 | $1,110 | $79 |
| Amlodipine Besylate | 88 | $1,094 | $12 |
| Oxycodone | 66 | $1,033 | $16 |
| Sodium Chloride | 51 | $1,022 | $20 |
| Prochlorperazine Maleate | 87 | $1,010 | $12 |
| Anastrozole | 28 | $1,009 | $36 |
| Lactulose | 30 | $896 | $30 |
| Gabapentin | 29 | $889 | $31 |
| Hydrocodone-Acetaminophen | 46 | $872 | $19 |
| Morphine Sulfate Er | 38 | $821 | $22 |
| Ondansetron | 14 | $651 | $46 |
| Constulose | 20 | $635 | $32 |
| Acyclovir | 13 | $558 | $43 |
| Potassium Chloride | 21 | $553 | $26 |
| Tamoxifen Citrate | 24 | $497 | $21 |
| Lidocaine-Prilocaine | 27 | $457 | $17 |
| Alendronate | 25 | $442 | $18 |
| Atorvastatin | 20 | $404 | $20 |
| Losartan | 16 | $386 | $24 |
| Loperamide | 16 | $370 | $23 |
| Tamsulosin | 11 | $356 | $32 |
| Duloxetine | 11 | $324 | $29 |
| Lorazepam | 48 | $281 | $6 |
| Diclofenac | 12 | $253 | $21 |
| Famotidine | 19 | $220 | $12 |
| Prednisone | 14 | $195 | $14 |
| Zolpidem | 18 | $162 | $9 |
| Furosemide | 20 | $97 | $5 |
| Lisinopril | 18 | $45 | $2 |
2021: 43 drugs
| Pomalyst | 17 | $311,995 | $18,353 |
| Nexavar | 14 | $305,452 | $21,818 |
| Imbruvica | 17 | $257,790 | $15,164 |
| Tagrisso | 11 | $184,195 | $16,745 |
| Xgeva | 13 | $35,179 | $2,706 |
| Eliquis | 44 | $29,158 | $663 |
| Creon | 12 | $23,875 | $1,990 |
| Xarelto | 17 | $11,098 | $653 |
| Sucralfate | 19 | $3,496 | $184 |
| Enoxaparin | 15 | $3,017 | $201 |
| Narcan | 17 | $2,330 | $137 |
| Nystatin | 22 | $1,759 | $80 |
| Morphine Sulfate Er | 50 | $1,483 | $30 |
| Dexamethasone | 37 | $1,441 | $39 |
| Hydrocodone-Acetaminophen | 33 | $1,300 | $39 |
| Tamoxifen Citrate | 36 | $1,245 | $35 |
| Hydroxyurea | 16 | $1,090 | $68 |
| Anastrozole | 21 | $1,068 | $51 |
| Prochlorperazine Maleate | 72 | $1,031 | $14 |
| Oxycodone | 40 | $1,030 | $26 |
| Potassium Chloride | 20 | $925 | $46 |
| Mirtazapine | 14 | $746 | $53 |
| Pantoprazole | 23 | $693 | $30 |
| Lactulose | 21 | $668 | $32 |
| Chlorthalidone | 11 | $633 | $58 |
| Celecoxib | 12 | $633 | $53 |
| Ondansetron | 38 | $598 | $16 |
| Amlodipine Besylate | 49 | $515 | $11 |
| Levothyroxine | 21 | $460 | $22 |
| Lidocaine-Prilocaine | 14 | $390 | $28 |
| Acyclovir | 20 | $313 | $16 |
| Omeprazole | 16 | $304 | $19 |
| Loperamide | 11 | $291 | $26 |
| Gabapentin | 16 | $280 | $18 |
| Alendronate | 22 | $236 | $11 |
| Prednisone | 21 | $209 | $10 |
| Atorvastatin | 18 | $194 | $11 |
| Lorazepam | 38 | $172 | $5 |
| Lisinopril | 31 | $151 | $5 |
| Sulfamethoxazole-Trimethoprim | 14 | $132 | $9 |
| Clonazepam | 18 | $117 | $7 |
| Tramadol | 13 | $46 | $4 |
| Alprazolam | 11 | $9 | $1 |
2020: 33 drugs
| Pomalyst | 19 | $348,460 | $18,340 |
| Xtandi | 21 | $215,232 | $10,249 |
| Tagrisso | 13 | $208,718 | $16,055 |
| Revlimid | 12 | $135,272 | $11,273 |
| Eliquis | 27 | $27,058 | $1,002 |
| Xarelto | 23 | $24,542 | $1,067 |
| Creon | 21 | $18,622 | $887 |
| Sucralfate | 15 | $4,029 | $269 |
| Narcan | 20 | $2,575 | $129 |
| Mirtazapine | 19 | $1,841 | $97 |
| Dexamethasone | 39 | $1,470 | $38 |
| Nystatin | 20 | $1,386 | $69 |
| Tamoxifen Citrate | 28 | $1,212 | $43 |
| Hydroxyurea | 20 | $1,194 | $60 |
| Prochlorperazine Maleate | 53 | $1,192 | $22 |
| Chlorthalidone | 17 | $1,116 | $66 |
| Morphine Sulfate Er | 25 | $635 | $25 |
| Lactulose | 23 | $628 | $27 |
| Ondansetron | 28 | $595 | $21 |
| Clotrimazole | 11 | $542 | $49 |
| Oxycodone | 28 | $533 | $19 |
| Diphenoxylate-Atropine | 17 | $458 | $27 |
| Hydrocodone-Acetaminophen | 17 | $412 | $24 |
| Omeprazole | 16 | $387 | $24 |
| Anastrozole | 28 | $359 | $13 |
| Levothyroxine | 14 | $320 | $23 |
| Acyclovir | 11 | $246 | $22 |
| Amlodipine Besylate | 37 | $243 | $7 |
| Prednisone | 16 | $200 | $13 |
| Lorazepam | 15 | $125 | $8 |
| Potassium Chloride | 11 | $88 | $8 |
| Alendronate | 11 | $80 | $7 |
| Zolpidem | 11 | $39 | $4 |
2019: 7 drugs
| Tagrisso | 19 | $291,719 | $15,354 |
| Nystatin | 13 | $772 | $59 |
| Dexamethasone | 14 | $536 | $38 |
| Morphine Sulfate Er | 14 | $239 | $17 |
| Prochlorperazine Maleate | 15 | $232 | $15 |
| Ondansetron | 14 | $168 | $12 |
| Lorazepam | 11 | $27 | $2 |
2018: 9 drugs
| Tagrisso | 13 | $225,631 | $17,356 |
| Creon | 14 | $14,930 | $1,066 |
| Nystatin | 20 | $874 | $44 |
| Oxycodone | 25 | $576 | $23 |
| Ondansetron | 21 | $506 | $24 |
| Dexamethasone | 20 | $439 | $22 |
| Pantoprazole | 14 | $309 | $22 |
| Potassium Chloride | 14 | $135 | $10 |
| Lorazepam | 15 | $75 | $5 |
2017: 9 drugs
| Xtandi | 14 | $140,460 | $10,033 |
| Zenpep | 12 | $5,877 | $490 |
| Mirtazapine | 18 | $1,289 | $72 |
| Ondansetron | 30 | $711 | $24 |
| Nystatin | 24 | $585 | $24 |
| Oxycodone | 23 | $511 | $22 |
| Prochlorperazine Maleate | 31 | $484 | $16 |
| Dexamethasone | 20 | $207 | $10 |
| Lorazepam | 13 | $89 | $7 |
Money from drug and device companies
$1,226 in 2025
| 2025 | 8 | 10 | $925 | $1,226 |
| 2024 | 4 | 5 | $3,642 | $3,667 |
| 2023 | 7 | 8 | $43,795 | $43,816 |
| 2022 | 4 | 4 | $1,283 | $1,316 |
| 2021 | 7 | 9 | $1,317 | $1,493 |
| 2020 | 7 | 14 | $25,269 | $25,428 |
| 2019 | 17 | 31 | $21,363 | $22,055 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| TerSera Therapeutics | Margenza | $452 | 1 payment
|
| Dr.Reddy's Laboratories | None | $260 | 1 payment
|
| Leica Microsystems | None | $213 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $121 | 1 payment
|
| Celgene | Reblozyl | $87 | 3 payments
|
| Pfizer | Padcev | $37 | 1 payment
|
See all 10 published payments
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-04 | Lynparza | $121 |
| Pfizer | Meals · 2025-10-09 | Padcev | $37 |
| Celgene | Meals · 2025-10-07 | Reblozyl | $31 |
| Celgene | Meals · 2025-10-02 | Reblozyl | $24 |
| Astellas Pharma US | Meals · 2025-09-18 | Vyloy | $30 |
| Leica Microsystems | Paid to speak or teach · 2025-09-08 | None | $213 |
| TerSera Therapeutics | Consulting · 2025-05-20 | Margenza | $452 |
| Adc Therapeutics America | Meals · 2025-04-16 | Zynlonta | $26 |
| Celgene | Meals · 2025-03-20 | Reblozyl | $32 |
| Dr.Reddy's Laboratories | Consulting · 2025-03-11 | None | $260 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $3,667
| AstraZeneca Pharmaceuticals LP | Lynparza | $2,745 | 2 payments
|
| BeiGene USA | None | $517 | 1 payment
|
| Halozyme | None | $380 | 1 payment
|
| Pfizer | Padcev | $25 | 1 payment
|
2023: $43,816
| Foundation Medicine | Foundationone Cdx | $40,649 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $1,388 | 1 payment
|
| Lantheus Medical Imaging | None | $550 | 1 payment
|
| Becton Dickinson and | None | $508 | 1 payment
|
| BeiGene | Brukinsa | $500 | 1 payment
|
| Daiichi Sankyo | None | $200 | 1 payment
|
| Mirati Therapeutics | Krazati | $21 | 1 payment
|
2022: $1,316
| Vertex Pharmaceuticals | None | $533 | 1 payment
|
| BeiGene USA | Brukinsa | $500 | 1 payment
|
| Alexion Pharmaceuticals | None | $250 | 1 payment
|
| GlaxoSmithKline | Zejula | $33 | 1 payment
|
2021: $1,493
| Genzyme | Cablivi | $700 | 2 payments
|
| Vertex Pharmaceuticals | None | $517 | 1 payment
|
| GlaxoSmithKline | None | $100 | 1 payment
|
| Janssen Biotech | Erleada | $100 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $37 | 2 payments
|
| Genentech USA | Rituxan | $20 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $19 | 1 payment
|
2020: $25,428
| Foundation Medicine | Foundationone Cdx | $24,844 | 3 payments
|
| GlaxoSmithKline | Zejula | $468 | 4 payments
|
| Pfizer | Xalkori | $38 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $23 | 1 payment
|
| AbbVie | Venclexta | $22 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $19 | 1 payment
|
| Kite Pharma | Yescarta | $14 | 1 payment
|
2019: $22,055
| Foundation Medicine | Foundationone Liquid | $21,268 | 2 payments
|
| Genzyme | Elitek | $164 | 6 payments
|
| Bayer HealthCare Pharmaceuticals | Vitrakvi | $124 | 1 payment
|
| Sanofi-Aventis U.S. | Jevtana | $100 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $60 | 3 payments
|
| Janssen Biotech | Darzalex | $47 | 3 payments
|
| Seattle Genetics | Adcetris | $43 | 2 payments
|
| Eisai | Halaven | $41 | 2 payments
|
| Pfizer | Bavencio | $39 | 3 payments
|
| Amgen | Mvasi | $23 | 1 payment
|
| Daiichi Sankyo | Injectafer | $23 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $22 | 1 payment
|
| Ipsen Biopharmaceuticals | Somatuline Depot | $22 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $21 | 1 payment
|
| Lilly USA | Verzenio | $20 | 1 payment
|
| Dova Pharmaceuticals | Doptelet | $19 | 1 payment
|
| Kyowa Kirin | Poteligeo | $17 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Boehringer Ingelheim Pharmaceuticals, Inc. · Phase I Bi907828 in Advance Tp53wt Mdm2 Amplified · 2019 | Their institution | $62,000 |
| Incyte Corporation · A Phase 1a1b Study Exploring the Safety and Tolerability of Incb081776 in Participants With Advanced Malignancies · 2019 | Their institution | $23,294 |
| E.R. Squibb & Sons, L.L.C. · Ph I II Fih Mono and Combo Nlrp3 Nivo Ipi in Advanced Solid Tumors · 2019 | Their institution | $9,809 |
| E.R. Squibb & Sons, L.L.C. · Ph I II Fih Mono and Combo Nlrp3 Nivo Ipi in Advanced Solid Tumors · 2020 | Their institution | $2,407 |
| E.R. Squibb & Sons, L.L.C. · Ph I/II Fih Mono and Combo (Nlrp3 + Nivo + Ipi) in Advanced Solid Tumors · 2022 | Their institution | $122 |
| E.R. Squibb & Sons, L.L.C. · Ph I/II Fih Mono and Combo (Nlrp3 + Nivo + Ipi) in Advanced Solid Tumors · 2023 | Their institution | $78 |
Professional record
- NPI
- 1912167420
- Licence
- CA A143956, MA L-236527California A143956: Current · expires 2027-09-30
- Trained
- Johns Hopkins University School of Medicine, 2008
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Palo Alto, CA, 94304
- NPI first listed
- 2008-06-10
- NPI last updated
- 2024-04-28
- NPI record certified
- 2024-04-28
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: Massachusetts General Hospital, Boston, MA, 02114